We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Medpace (MEDP) Outpaced the Stock Market Today
Read MoreHide Full Article
Medpace (MEDP - Free Report) closed at $501.23 in the latest trading session, marking a +1.56% move from the prior day. This change outpaced the S&P 500's 1.02% gain on the day. Meanwhile, the Dow experienced a rise of 0.63%, and the technology-dominated Nasdaq saw an increase of 1.23%.
Shares of the provider of outsourced clinical development services have appreciated by 9.57% over the course of the past month, outperforming the Medical sector's loss of 4.81%, and the S&P 500's gain of 0.63%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on April 22, 2026. In that report, analysts expect Medpace to post earnings of $3.74 per share. This would mark year-over-year growth of 1.91%. Simultaneously, our latest consensus estimate expects the revenue to be $694.24 million, showing a 24.29% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $17.04 per share and a revenue of $2.81 billion, representing changes of +11.52% and +11.17%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Medpace presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 28.96. For comparison, its industry has an average Forward P/E of 15.51, which means Medpace is trading at a premium to the group.
We can also see that MEDP currently has a PEG ratio of 2.37. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. MEDP's industry had an average PEG ratio of 1.39 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Medpace (MEDP) Outpaced the Stock Market Today
Medpace (MEDP - Free Report) closed at $501.23 in the latest trading session, marking a +1.56% move from the prior day. This change outpaced the S&P 500's 1.02% gain on the day. Meanwhile, the Dow experienced a rise of 0.63%, and the technology-dominated Nasdaq saw an increase of 1.23%.
Shares of the provider of outsourced clinical development services have appreciated by 9.57% over the course of the past month, outperforming the Medical sector's loss of 4.81%, and the S&P 500's gain of 0.63%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on April 22, 2026. In that report, analysts expect Medpace to post earnings of $3.74 per share. This would mark year-over-year growth of 1.91%. Simultaneously, our latest consensus estimate expects the revenue to be $694.24 million, showing a 24.29% escalation compared to the year-ago quarter.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $17.04 per share and a revenue of $2.81 billion, representing changes of +11.52% and +11.17%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Medpace presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 28.96. For comparison, its industry has an average Forward P/E of 15.51, which means Medpace is trading at a premium to the group.
We can also see that MEDP currently has a PEG ratio of 2.37. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. MEDP's industry had an average PEG ratio of 1.39 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.